DrugPatentWatch Database Preview
Drugs in Development Information for Orteronel
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Orteronel?
Orteronel is an investigational drug.
There have been 17 clinical trials for Orteronel.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and University of Wisconsin, Madison.
There are five US patents protecting this investigational drug and forty-seven international patents.
Summary for Orteronel
| US Patents | 5 |
| International Patents | 47 |
| US Patent Applications | 15 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-11-01) |
| Vendors | 40 |
Recent Clinical Trials for Orteronel
| Title | Sponsor | Phase |
|---|---|---|
| AR-inhibitor Bicalutamide in Treating Patients With TNBC | Jiangsu Province Hospital of Traditional Chinese Medicine | Phase 2 |
| AR-inhibitor Bicalutamide in Treating Patients With TNBC | Nanning Second People's Hospital | Phase 2 |
| AR-inhibitor Bicalutamide in Treating Patients With TNBC | The First People's Hospital of Lianyungang | Phase 2 |
Clinical Trial Summary for Orteronel
Top disease conditions for Orteronel
Top clinical trial sponsors for Orteronel
US Patents for Orteronel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Orteronel | Start Trial | Modulation of androgen receptor expression | ISIS Pharmaceuticals Inc. (Carlsbad, CA) | Start Trial |
| Orteronel | Start Trial | Androgen receptor down-regulating agents and uses thereof | University of Maryland, Baltimore (Baltimore, MD) | Start Trial |
| Orteronel | Start Trial | Modulation of androgen receptor expression | Ionis Pharmaceuticals, Inc. (Carlsbad, CA) | Start Trial |
| Orteronel | Start Trial | Inhibitors of CYP17A1 | UNIVERSITY OF KANSAS (Lawrence, KS) | Start Trial |
| Orteronel | Start Trial | Androgen receptor down-regulating agents and uses thereof | University of Maryland, Baltimore (Baltimore, MD) University of Maryland Eastern Shore (Princess Anne, MD) Thomas Jefferson University (Philadelphia, PA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Orteronel
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Orteronel | Argentina | 092982 | 2032-10-11 | Start Trial |
| Orteronel | Australia | 2013329070 | 2032-10-11 | Start Trial |
| Orteronel | Australia | 2017200759 | 2032-10-11 | Start Trial |
| Orteronel | Brazil | 112015007878 | 2032-10-11 | Start Trial |
| Orteronel | Canada | 2887867 | 2032-10-11 | Start Trial |
| Orteronel | Chile | 2015000901 | 2032-10-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
